These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 1164848)

  • 1. The effect of progestin R 2323 released from vaginal rings on ovarian function.
    Johansson ED; Luukkainen T; Vartiainen E; Victor A
    Contraception; 1975 Sep; 12(3):299-307. PubMed ID: 1164848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravaginal contraception with the synthetic progestin, R2010.
    Toivonen J
    Contraception; 1979 Nov; 20(5):511-8. PubMed ID: 527342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of ovarian function with the transdermally given synthetic progestin ST 1435.
    Laurikka-Routti M; Haukkamaa M; Lähteenmäki P
    Fertil Steril; 1992 Oct; 58(4):680-4. PubMed ID: 1426309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of four different contraceptive vaginal rings: steroid serum levels, luteal activity, bleeding control and lipid profiles.
    Alvarez-Sanchez F; Brache V; Jackanicz T; Faundes A
    Contraception; 1992 Oct; 46(4):387-98. PubMed ID: 1486777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of a synthetic progestogen, ethylnorgestrienone, on hypothalamic-pituitary-ovarian function, cervical mucus, vaginal cytology, and endometrial morphology.
    Niaraki MA; Moghissi KS; Borin K
    Fertil Steril; 1981 Mar; 35(3):284-8. PubMed ID: 6781938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical performance and endocrine profiles with contraceptive vaginal rings containing a combination of estradiol and d-norgestrel.
    Mishell DR; Moore DE; Roy S; Brenner PF; Page MA
    Am J Obstet Gynecol; 1978 Jan; 130(1):55-62. PubMed ID: 619648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioimmunoassay of serum medroxyprogesterone acetate (Provera) in women following oral and intravaginal administration.
    Hiroi M; Stanczyk FZ; Goebelsmann U; Brenner PF; Lumkin ME; Mishell DR
    Steroids; 1975 Sep; 26(3):373-86. PubMed ID: 1198624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravaginal contraception with the synthetic progestin, R2323.
    Akinla O; Lähteenmäki P; Jackanicz TM
    Contraception; 1976 Dec; 14(6):671-8. PubMed ID: 1017201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial clinical studies of intravaginal rings containing norethindrone and norgestrel.
    Mishell DR; lumkin M; Jackanicz T
    Contraception; 1975 Sep; 12(3):253-60. PubMed ID: 1164845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of a single contraceptive Silastic implant containing nomegestrol acetate on ovarian function and cervical mucus production during 2 years.
    Barbosa I; Coutinho E; Hirsch C; Ladipo O; Olsson SE; Ulmsten U
    Fertil Steril; 1996 Apr; 65(4):724-9. PubMed ID: 8654629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Morphometric study of the human endometrium following continuous exposure to levonorgestrel released from vaginal rings during 90 days.
    Johannisson E; Brosens I; Cornillie F; Elder M; White J; Sheppard B; Hourihan H; d'Arcangues C; Belsey EM
    Contraception; 1991 Apr; 43(4):361-74. PubMed ID: 1906792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamics of a contraceptive vaginal ring releasing 3-keto-desogestrel.
    Jackson R; Newton JR
    Contraception; 1989 Jun; 39(6):653-64. PubMed ID: 2752753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of short-term cyclic administration of cyproterone acetate on pituitary-ovarian function in the human.
    Kumari GI; Das RP; Madoiya KK; Jain AK; Roy S
    Fertil Steril; 1977 Nov; 28(11):1168-74. PubMed ID: 562781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A clinical pharmacological study of a new type of vaginal delivery system for levonorgestrel.
    Landgren BM; Johannisson E; Xing S; Aedo AR; Diczfalusy E
    Contraception; 1985 Dec; 32(6):581-601. PubMed ID: 3937664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A contraceptive subdermal implant releasing the progestin ST-1435: ovarian function, bleeding patterns, and side effects.
    Laurikka-Routti M; Haukkamaa M
    Fertil Steril; 1992 Dec; 58(6):1142-7. PubMed ID: 1459263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of weekly administration of an oral progestogen -R 2323- on the ovarian function.
    Victor A; Johansson ED
    Contraception; 1975 Jul; 12(1):89-94. PubMed ID: 1139951
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical performance and endocrine profiles with contraceptive vaginal rings containing a combination of estradiol and D-norgestrel.
    Mehta S; Joshi UM; Sankolli GM; Adatia A; Donde UM; Saxena BN
    Contraception; 1981 Mar; 23(3):241-50. PubMed ID: 7238044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response.
    Kalogirou D; Antoniou G; Karakitsos P; Kalogirou O; Antoniou D; Giannikos L
    Int J Fertil Menopausal Stud; 1996; 41(6):522-7. PubMed ID: 9010746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contraception with a vaginal ring releasing 3-keto desogestrel and ethinylestradiol.
    Olsson SE; Odlind V
    Contraception; 1990 Nov; 42(5):563-72. PubMed ID: 2272184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The plasma concentration of a synthetic progestin, R 2323, released from polysilastic vaginal rings.
    Viinikka L; Victor A; Jänne O; Raynaud JP
    Contraception; 1975 Sep; 12(3):309-16. PubMed ID: 1164849
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.